can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.
Company profile
Ticker
CANF
Exchange
Website
CEO
Pnina Fishman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CANF stock data
Latest filings (excl ownership)
6-K
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
15 Apr 24
EFFECT
Notice of effectiveness
10 Apr 24
S-8
Registration of securities for employees
5 Apr 24
POS AM
Prospectus update (post-effective amendment)
5 Apr 24
6-K
Report of Foreign Private Issuer
3 Apr 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
6-K
Report of Foreign Private Issuer
11 Mar 24
6-K
Patent has already been issued in other major markets including the U.S., EU, Japan and China
28 Feb 24
6-K
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
Transcripts
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
9 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G
ARMISTICE CAPITAL, LLC
19 Jun 20
SC 13G
CVI Investments, Inc.
19 Jun 20
SC 13G
Can-Fite BioPharma Ltd.
20 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 218.46 mm |
Total shares | 62.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 39.50 mm | $50.95 mm |
CVI Investments | 23.16 mm | $0.00 |
MS Morgan Stanley | 33.31 k | $102.25 mm |
Rhumbline Advisers | 17.10 k | $52.51 mm |
FITB Fifth Third Bancorp | 3.00 k | $9.21 mm |
National Bank of Canada | 600.00 | $1.84 mm |
C Citigroup | 553.00 | $1.70 mm |
Proequities | 0.00 | $0.00 |
News
Can-Fite's Namodenoson Featured in Biomedicines for Liver Cancer and MASH Treatment Insights
15 Apr 24
Can-Fite BioPharma Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
3 Apr 24
Can Fite Biofarma: Q4 Earnings Insights
28 Mar 24
Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
28 Mar 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
Press releases
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
15 Apr 24
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
3 Apr 24
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
11 Mar 24
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
28 Feb 24